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Change in Markers of Bone Metabolism with Chemotherapy 
for Advanced Prostate Cancer: Interleukin-6 Response Is a 
Potential Early Indicator of Response to Therapy
Kathleen M. Woods Ignatoski,1 Judah Friedman,2 June Escara-Wilke,1 Xiaohua Zhang,1 Stephanie Daignault,3 
Rodney L. Dunn,1 David C. Smith,1,2,4 and Evan T. Keller1,4
Men with androgen-independent prostate cancer (AIPC) frequently have bone metastasis. The effects of chemo-
therapy on markers of bone metabolism have not been well characterized. We conducted a prospective study of 
patients with AIPC randomized in the fi rst cycle to receive either docetaxel/estramustine or zoledronic acid, a 
bisphosphonate, to inhibit osteoclastic activity. Here we report the effects of therapy on markers of bone metab-
olism in these patients following the fi rst cycle of therapy. Serum levels of several indices of bone remodeling 
were evaluated using commercial enzyme-linked immunosorbent assays. Changes in markers of bone metabo-
lism were compared in patients receiving initial chemotherapy versus bisphosphonate. There was no signifi cant 
difference in median change in any of the measured bone markers in patients given zoledronic acid when com-
pared to chemotherapy. When comparing responders to nonresponders, overall interleukin-6 (IL-6) decreased 
by 35% in prostate-specifi c antigen responders; whereas, IL-6 levels increased by 76% in nonresponders (p = 
0.03). Elevated IL-6 levels and reductions in IL-6 levels early in treatment may refl ect ultimate clinical response 
to docetaxel-based regimens.
Introduction
Metastatic, androgen-independent prostate cancer (AIPC) is a bone predominant disease, and therapy 
directed specifi cally at bone metastases has shown signifi cant 
clinical benefi t. Zoledronic acid (Zometa™), one of the most 
potent of the new generation bisphosphonates, is effective in 
reducing skeletal related events and bone pain in metastatic 
AIPC (Saad and others 2004a). Zoledronic acid’s primary 
mechanism of action involves inhibition of osteoclast activ-
ity. Although characterized primarily by osteoblastic bone 
lesions, it is clear that AIPC has an osteolytic component 
(Keller 2002) which probably accounts for the clinical bene-
fi t of bisphosphonates in AIPC. In addition to its anti-osteo-
clastic effect, there are controversial data suggesting that 
bisphosphonates have a direct antitumor effect (Berenson 
2005; Brubaker and others 2006). Unlike bisphosphonates, the 
effects of chemotherapy alone on markers of bone metabolism 
have not been well characterized. Docetaxel-based regimens 
are frequently used in patients with AIPC and have proven 
clinical and survival benefi ts. Because AIPC metastasizes 
to bone, we hypothesized that therapy induced changes in 
levels of bone metabolism markers could serve as an early 
biomarker of therapeutic clinical response.
For this study, we obtained levels of several markers of 
bone metabolism from men with AIPC that had bone metas-
tases who were enrolled on a study of docetaxel-based 
chemotherapy. We studied markers of bone resorption, 
including receptor activator of nuclear-κ B ligand (RANKL), 
tartrate-resistant acid phosphatase (TRAPC), and urinary 
deoxypyridinolines (DpDs). Soluble or cell membrane 
attached RANKL activates its receptor, RANK, which is a 
member of the tumor necrosis factor receptor family and 
is critical in driving osteoclast activation and bone resorp-
tion (Wittrant and others 2004). In human PCa cell lines and 
primary samples, RANKL/RANK expression correlates 
with more aggressive and advanced metastatic PCa (Brown 
and others 2001; Chen and others 2006). TRAPC is secreted 
by active osteoclasts and correlates with resorptive biol-
ogy (Rummukainen and others 2001; Kirstein and others 
2006). DpD is a validated biomarker of bone resorption in 
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Treatment
Patients were randomized to treatment with either zole-
dronic acid alone or docetaxel and estramustine for the fi rst 
cycle of therapy. All subsequent cycles consisted of all three 
drugs. Docetaxel 70 mg/m2 was given on day 2 of a 21-day 
cycle, and estramustine 280 mg was given orally three times 
per day on days 1–3. Premedication with oral dexametha-
sone 8 mg by mouth was given every 12 h, beginning prior 
to each planned dose of docetaxel and continuing for a total 
of 4 doses over 3 days, Zoledronic acid 4 mg was given intra-
venously on day 2 for over 15 min and continued monthly. 
All patients remained on primary androgen ablation during 
chemotherapy. All patients initially received three courses 
of therapy.
Bone marker assays
Measurement of bone markers occurred prior to initiat-
ing treatment on trial, on day 2 of cycle 2 (prior to initiation 
of zoledronic acid and docetaxel/estramustine together), 
and at intervals during treatment and observation. Urinary 
DpD was measured using an enzyme-linked immunosor-
bent assay (ELISA) as recommended by the manufacturer 
(Pyrilinks-D, Metra Biosystems, Mountain View, CA). 
Urinary creatinine was measured using a chemical assay kit 
(Metra Biosystems). DpD was then corrected for variations 
in the urine concentration by normalizing to urine creati-
nine values. Results are reported as DpD (nmol/mmol cre-
atinine). BAP was measured by an enzyme immunoassay 
(EIA) (Alkphase-B, Metra Biosystems). Intact OCN was mea-
sured by competitive EIA (NovoCalcin, Metra Biosystems). 
IL6, RANK, OPG, and TRAPC were measured by commer-
cially available ELISAs (Quantikine HS human IL-6, R&D 
Systems; sRANKL, ALPCO Diagnostics; OPG, ALPCO 
Diagnostics; Bone TRAP Assay, IDS).
Statistics
The relative difference in each bone marker (IL-6, DpD, 
TRAPC, BAP, OCN, OCN, and OPG) was the unit of analy-
sis. This adjusts for the baseline differences with negative 
numbers representing the percent decrease from baseline 
and positive numbers representing the percent increase 
from baseline. The actual difference from baseline was 
used to analyze RANKL due to a majority of baseline val-
ues being zero. The median and range for each marker is 
reported by initial treatment group, zoledronic acid ver-
sus docetaxel/estramustine, and by responder versus non-
responder. Medians were used as the data were skewed 
and a mean value would not be representative of the data. 
Comparisons were tested using the Wilcoxon Rank test. In 
the same manner, baseline values of each bone marker were 
analyzed by responder versus nonresponder. All analyses 




The average patient was 68 years old (range 50–81) and 
Caucasian (96%). The majority of patients had bone metasta-
ses without visceral or lymphatic metastases detected (68%). 
multiple types of malignancies. The process of bone resorp-
tion results in the production of collagen breakdown prod-
ucts that are excreted in the urine (Pecherstorfer and others 
1997; Garnero and others 2000a; Saad and others 2004b). 
Bisphosphonates have been shown to decrease DpD levels in 
patients with skeletal metastases (Coleman and others 1999). 
We studied markers of bone production including alkaline 
phosphatase [bone-specifi c alkaline phosphatase (BAP)] and 
intact osteocalcin (OCN); both are products of bone produc-
tion that have been studied as markers of bone metastases in 
advanced AIPC (Coleman and others 1988; Francini and oth-
ers 1988; Marcellini and others 1992; Jung and others 2004; 
Cook and others 2006). We also studied serum interleukin 6 
(IL-6) and osteoprotegerin (OPG). IL-6 has been implicated 
in prostate cancer progression, chemotherapeutic resistance, 
and androgen independence and bone remodeling (Ershler 
and Keller 2000; Smith and others 2001; Domingo-Domenech 
and others 2006; Dattoli and others 2007). OPG is a soluble 
decoy receptor for RANKL and, therefore, interferes with 
osteoclast activation (Wittrant and others 2004). Here, we 
report on the effects of a docetaxel-based regimen compared 
to zoledronic acid on markers of bone metabolism following 
the fi rst cycle of therapy.
Materials and Methods
This prospective study was reviewed and approved by 
the Institutional Review Board of the University of Michigan 
and was monitored under the National Cancer Institute–
approved Data and Safety Monitoring Plan of the University 
of Michigan Comprehensive Cancer Center. After providing 
signed, written informed consent, participants were regis-
tered and randomized to treatment. Patients were eligible 
if they had histologically confi rmed adenocarcinoma of the 
prostate that was metastatic to bone based on a bone scan 
and had become androgen independent. Androgen indepen-
dence was demonstrated by the appearance of new lesions on 
bone scan or computerized tomography and/or an increase 
in prostate-specifi c antigen (PSA) of 50% over nadir value on 
hormone therapy measured on two successive occasions at 
least 2 weeks apart, and the second PSA value must have been 
≥5.0ng/dL. Patients on androgen suppression therapy under-
went nonsteroidal antiandrogen withdrawal (4 weeks after 
withdrawal of fl utamide and 6 weeks for biclutamide) with 
evidence of progression. A Zubrod performance status of 2 or 
more was required. A ≥50% decline in PSA without evidence 
of progression by bone or CT scan indicated a responder. 
Progression was defi ned as the appearance of new lesions 
in bone or soft tissue. Worsening of existing bone lesions 
was not considered criteria for progression. The assessment 
of response and progression used the consensus criteria 
described by Bubley and others (1999). There was no progres-
sion in measurable disease in those coded as responders.
No concurrent chemotherapy, biologic therapy, or other 
investigational anticancer therapy was allowed. No prior 
taxane-based cytotoxic chemotherapy for androgen-inde-
pendent disease was allowed. Prior to initiation of chemo-
therapy, a granulocyte count ≥1,500 cells/mm3, a platelet 
count ≥100,000 cells/mm3, and hemoglobin ≥8 gm/dL was 
required. Patients with a bilirubin greater than the upper 
limit of normal (ULN) or aspartate transaminase and ala-
nine transaminase ≥1.5× ULN, or serum creatinine ≥1.2× 
ULN were excluded.
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compared between responders and nonresponders. There 
was no signifi cant difference for any bone marker or PSA 
level between baseline values for responders versus nonre-
sponders (Table 2).
To determine whether therapy-induced changes of 
bone marker levels could predict response to chemother-
apy, we compared the changes in bone marker levels from 
baseline levels to after the initial cycle of therapy between 
responders and nonresponders. In patients who ultimately 
responded to therapy, IL-6 levels decreased by 35% com-
pared to the nonresponders, whose IL-6 levels increased by 
76% (p value = 0.03) (Fig. 1). Additionally, there was a trend 
(p value = 0.09) for OCN levels to decrease (40% decline) in 
responders with no change in the value observed in the non-
responders (not shown). There were no signifi cant changes 
for any of the other bone remodeling markers.
A previous study had shown that IL-6 levels corre-
lated with the extent of disease (EOD) based on bone scan 
(Akimoto and others 1998).
To determine if IL-6 correlated with EOD on bone 
scan in this study, we classifi ed the patients based on a 
 modifi cation of Soloway’s classifi cation system (Soloway 
and others 1988). In the original system, there were 5 
grades as follows: 0, normal; 1, number of bony metastases 
less than six, each of which is <50% the size of a vertebral 
body (one lesion about the size of a vertebral body would 
be counted as two lesions); 2, number of bone metastases 
between 6 and 20, size of lesions as described above; 3, 
number of  metastases more than 20 but less than a “super 
scan”; and 4, “superscan” or its equivalent, i.e., >75% of 
the ribs, vertebrae, and pelvic bones. We modifi ed this as 
we felt the difference between grade 3 and 4 was rather 
arbitrary and could not be  consistently decided. Thus, we 
classifi ed the patients on 4 grades as follows: 0, normal; 
1, ≤5 lesions; 2, 6–20 lesion; 3, >20 lesions. As the selec-
tion criteria for this study was the presence of a positive 
bone scan, there were no grade 0 scans. The patients were 
distributes as follows: Grade 1 = 11 patients; Grade 2 = 9 
patients; Grade 3 = 8 patients. There was no correlation 
with response and EOD. In contrast, IL-6 levels were ele-
vated in the Grade 3 patients compared to Grade 1 and 2 
patients (Fig. 2).
Additionally, most patients had attempted at least two dif-
ferent hormone manipulations prior to enrollment (range 
1–4). Fifty percent of the patients had received a radical 
prostatectomy.
Fourteen of the 28 enrolled patients (50%) demonstrated a 
≥50% decline in PSA levels following a total of three cycles 
of therapy and were therefore classifi ed as responders to 
chemotherapy. The median PSA level was 89 ng/mL (range 
0.4–2620) and the median Gleason score was 8 (range 6–10). 
Fourteen patients were given zoledronic acid and 14 patients 
were given estramustine/docetaxel plus dexamethasone for 
the fi rst cycle. After the fi rst cycle, all patients received both 
treatments.
Bone marker data are available for 26 of the 28 patients 
at baseline and after the fi rst treatment cycle. After treat-
ment cycle 3, only 17 patients remained on the trial, most 
of which were responders. Therefore, any data after cycle 
3 cannot be used to draw conclusions about response due 
to withdrawal from the study of mostly the nonresponsive 
patients.
Biomarkers
To determine whether therapy had an effect on bone 
markers, the change in each bone marker between baseline 
and after the fi rst cycle of therapy was examined for each 
treatment group. Both zoledronic acid (Z) alone and the 
combination of docetaxel/estramustine (DE) alone resulted 
in a decline of OCN and TRAPC (Table 1). However, there 
was no signifi cant difference in the median change in any 
of the measured bone markers in patients that received Z 
versus DE. Z alone had no impact on PSA levels; whereas DE 
did decrease PSA levels (Table 1). This resulted in a signif-
icant difference in PSA response between the Z versus DE 
groups.
Response was determined as a decline in PSA levels by 
>50% after three cycles. The number of responders and non-
responders was similar in each treatment group, 8 respond-
ers and 6 nonresponders, indicating that the initial treatment 
alone did not account for response.
To determine if pretreatment levels of biomarkers 
could be used to predict response, values at baseline were 
Table 1. Median Change Relative to Pretreatment in Bone Markers after 
Cycle 1 of Zoledronic Acid or Docetaxel/Estramustine
Bone markera 
Zoledronic acid Docetaxel/estramustine
p value Number Median (range) Number Median (range)
BAP 13   −0.04 (−0.33, 1.31) 13 −0.15 (−0.59, 0.47) 0.58
DpD 12       0.40 (−0.97, 35.4) 13      0.0 (−0.98, 20.7) 0.81
IL-6 13    −0.12 (−12.2, 4.2) 13    0.15 (−0.83, 3.5) 0.51
OCN 13    −0.16 (−0.43, 63.4) 13 −0.43 (−0.68, 1.05) 0.11
OPG 13       0.10 (−0.38, 0.64) 12    0.06 (−0.48, 1.44) 0.73
TRAPC 13   −0.46 (−1.0, 0.25) 13 −0.39 (−1.1, 2.0) 0.27
RANKL* 13  −0.004 (−0.21, 8.0) 13 −0.01 (−0.19, 1.31) 0.76
PSA 13         0.0 (−0.84, 2.1) 13 −0.28 (−0.77, 0.09) 0.01
aInterleukin-6 (IL-6), urinary deoxypyridinoline to serum creatinine ratio (DpD), tartrate-
resistant acid phosphatase (TRAPC), bone-specifi c alkaline phosphatase (BAP), intact osteocalcin 
(OCN), and osteoprotegerin (OPG), ligand for receptor activator of nuclear-factor κB (RANKL), 
prostate-specifi c antigen (PSA). *Values represent actual difference rather than relative difference.
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Discussion
Indices of bone remodeling are upregulated in men with 
AIPC as most of these men have bone metastasis. Zoledronic 
acid is used to slow progression of bone disease associated 
with AIPC; however, evaluation of the activity of zoledronic 
acid versus an AIPC chemotherapy regimen has not been 
studied. Therefore, we determined bone marker levels in 
patients that were randomized to zoledronic acid infusion or 
docetaxel/estramustine for one cycle of treatment. There were 
no differences in the change in any marker of bone metabo-
lism when comparing the two groups. These data suggest that 
chemotherapy with docetaxel and estramustine may result 
in the stabilization of bone lesions to a degree similar to that 
seen with zoledronic acid. This raises the question of whether 
there is any benefi t to using both approaches in this popu-
lation. Alternatively, there may be an additive effect. These 
questions will need to be resolved in subsequent studies.
In our study, the median DpD level was slightly elevated 
at baseline (data not shown); however, we also found that 
urinary DpD levels did not signifi cantly decrease in patients 
given zoledronic acid alone for the fi rst cycle. These data 
suggest that measures of bone resorption may not be the 
appropriate way to follow PCa progression. Our data are 
in contrast to the decrease in type I collagen C-telopeptides 
(urine assay of bone resorption) observed after admin-
istration of bisphosphonates in patients with metastatic 
PCa(Garnero and others 2000a). The contrasting data could 
be due to the time point we used, being too early in treat-
ment, to see a difference in NTx, a component of the DpD 
assay.
We also compared the median change in bone markers 
in patients who responded to combination chemotherapy 
to those who did not. Changes in two serum markers dif-
fered in this comparison. IL-6, an infl ammatory cytokine, 
has been implicated by our group in PCa growth, pro-
gression, and androgen independence (Dattoli and others 
2007). IL-6 is a target gene of nuclear factor κB (NF-κB), a 
transcription factor implicated in PCa progression and bio-
chemical relapse (Karin and others 2004; Ross and others 
2004; Le Page and others 2005; Domingo-Domenech and 
others 2006). Docetaxel induces NF-κB and IL-6 in PCa cell 
lines (Domingo-Domenech and others 2006); however, we 


































FIG. 1. Changes in serum IL-6 levels predict response to 
therapy. Bone scan positive patients with prostate cancer were 
given either zoledronic acid (Z) alone or the combination of 
docetaxel and estramustine (DE) for an initial cycle followed 
by two additional treatment cycles of all three drugs. Serum 
IL-6 levels were measured pretreatment and postinitial cycle. 
Prostate-specifi c antigen (PSA) was measured pretreatment 
and at each cycle. A ≥50% decline in PSA without evidence of 
progression by bone or CT scan was considered a responder. 
Results are reported as relative change from the baseline 
(pretreatment) value. Data are shown as a whisker-box plots 
based on response. The bottom of the box is the 25th percen-
tile, the line through the box is the median, the top of the box 
is the 75th percentile, the top whisker cross bar is the maxi-
mum value in the upper quartile range, the bottom whisker 
cross bar is the minimum value in the lower quartile range, x 
= mean, + = outlier and #p = 0.03 versus nonresponders.
Table 2. Baseline Values Between Responders and Non-responders
Bone markera
Responders Nonresponders
p valueNumber Median (range) Number Median (range)
BAP 14 46.7 (16.4, 359.0) 7 52.6 (29.8, 378.0) 0.63
DpD 14   6.8 (1.3, 86.3) 7 51.1 (2.2, 422.8) 0.18
IL-6 14   3.0 (−0.86, 9.7) 7   1.8 (−0.84, 17.2) 0.26
OCN 14  15.1 (6.1, 37.4) 7 12.4 (7.6, 45.7) 0.58
OPG 14   4.1 (0, 10.6) 7 6.93 (2.7, 9.5) 0.09
TRAPC 14   4.5 (0.88, 18.9) 7   5.4 (2.0, 17.6) 0.69
RANKL 14 0.03 (−0.14, 0.23) 7 0.07 (−0.05, 0.09) 0.88
PSA 14 99.3 (8.1, 2620) 8 75.7 (0.4, 815) 0.61
aSame abbreviations as in Table 1.
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(p = 0.14), thus indicating the results are consistent over the 
duration of the study.
One small study obtained IL-6 levels before and after one 
cycle of docetaxel treatment (Domingo-Domenech and oth-
ers 2006). In that study, it was shown that high levels of base-
line IL-6 were associated with poor response to docetaxel 
treatment and that 16 pg/mL of IL-6 was the transition point 
between high and low IL-6 levels. In our study, we have only 
one patient with a baseline IL-6 level higher than 16 pg/mL. 
Therefore, our cohort of patients all had serum IL-6 levels in 
the range of the responders in that previous report except 
for one. Our data suggests that within the group of patients 
with IL-6 levels below 16 pg/mL there are subsets of patients 
that are responders and nonresponders and that the change 
in IL-6 levels in response to therapy can predict which group 
these patients are in.
Intact OCN, a marker of bone formation, may also be an 
early indicator of response. OCN decreased by 40% after the 
fi rst cycle of therapy in those who ultimately were deter-
mined to be responders to at least three cycles of chemo-
therapy. When compared to the nonresponders, who had 
no reduction in OCN, the change in OCN between baseline 
and the end of the fi rst cycle was near statistical signifi cance. 
(p = 0.09). As skeletal metastases in PCa are osteoblastic, or 
bone forming, this observed decrease may refl ect a reduc-
tion in bone disease in responders to chemotherapy. If con-
fi rmed in a larger sample size then measurement of intact 
OCN may offer a more reliable way to assess bone turnover 
in osteoblastic bone disease.
increased in nonresponders regardless of the initial treat-
ment (Fig. 1). The76 % increase observed in IL-6 levels seen 
in those patients who are ultimately nonresponders may be 
indicative of increased disease burden, taxane-resistance, or 
more aggressive PCa biology. The increase in IL-6 levels in 
nonresponders, and decrease in responders was also evident 
in those who were given docetaxel/estramustine alone for the 
fi rst cycle (data not shown). These data indicate that follow-
ing IL-6 levels in patients on taxane-based regimens may be 
a useful way to predict emerging chemotherapy resistance.
One potential confounding factor is that dexametha-
sone has been shown to decrease IL-6 (Ray and others 1990). 
However, because there were the same number of responders 
and nonresponders in both the Z only and the DE treatment 
groups, the addition of dexamethasone in the DE treatment 
arm for the fi rst cycle did not account for the decline of IL-6 
observed in these patients.
We also compared the baseline IL-6 values between 
responders and nonresponders, but they were not signifi -
cantly different. Although not statistically signifi cant, these 
data indicate that responders typically started with high 
IL-6 levels that dropped dramatically with one cycle of treat-
ment; whereas, nonresponders started with lower baseline 
IL-6 levels that didn’t drop as much or increased. However, 
due to the small number of patients in our study, we could 
not pinpoint a cutoff value for “high” and “low” baseline 
IL-6. Additionally, we found that the IL-6 levels post-cycle 
3 were similar to those post-cycle 1. Specifi cally, there was 





























FIG. 2. The extent of bone metastatic disease 
correlates with serum IL-6 expression. Patients 
were classifi ed into the categories indicated for 
their extent of disease based on bone scans. 
Baseline (pretreatment) serum IL-6 levels were 
measured. Results are reported as median IL-6 
level (pg/mL). Data are shown as a whisker-
box plots based on response. The bottom of 
the box is the 25th percentile, the line through 
the box is the median, the top of the box is the 
75th percentile, the top whisker cross bar is the 
maximum value in the upper quartile range, 
the bottom whisker cross bar is the minimum 
value in the lower quartile range, x = mean, 
+ = outlier and #p = 0.04 versus ≤5.
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A number of other studies have been published study-
ing bone turnover markers as a sign of disease (Garnero and 
others 2000b; Jung and others 2004) or progression (Tamada 
and others 2001; Pectasides and others 2005; Chen and oth-
ers 2006; Cook and others 2006; Johansen and others 2007; 
Scher and others 2007). Studies on the presence of disease 
show that BAP or NTx, another collagen breakdown prod-
uct, correlate with survival. And studies on disease progres-
sion suggest that NTx correlates with type and bulk of bone 
disease. Taken together, these data indicate that bone mark-
ers are a sign of progression. A recent paper by Lein and 
others (2007) studied six bone markers after patients started 
zoledronic acid treatment for metastatic bone disease. The 
data presented in that paper (Lein and others 2007) did not 
show a signifi cant correlation between baseline values of the 
bone markers and progression, but did show a signifi cant 
association of increased bone markers (not including CTx) 
over the course of the study to disease progression. Our 
study adds another dimension to the use of bone markers to 
predict outcome.
We would like to note that multiple comparisons adjust-
ments were not used for analysis of the bone markers by 
response as this was a secondary end point of this study. We 
were looking to detect a signal that would allow us to poten-
tially detect patients who are likely to respond. The study 
was not powered to examine bone markers as an index of 
response as a primary end point.
The data we present here are the fi rst to describe the 
changes in bone markers with chemotherapy for prostate 
cancer and compare them to those seen with bisphospho-
nates. These are also the fi rst data to show an association 
between a change in serum IL-6 and response. By measur-
ing multiple markers of bone turnover in response to che-
motherapy, we may be able to validate a novel way to follow 
disease progression or chemotherapy resistance in future 
chemotherapy trials. These studies provide a strong ratio-
nale to validate changes in IL-6 levels as an early indicator of 
response in a larger prospective clinical trial. If these results 
are validated in a larger trial, then IL-6 response could serve 
as an early indicator of response to therapy and rises in IL-6 
during early therapy would suggest that chemotherapy is 
not working and an alternative therapy should be used.
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